Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human test for new cancer imaging tracer

NCT ID NCT05799274

Summary

This early-stage study aims to understand the safety and radiation exposure of an experimental imaging agent called RAD301. It will involve 9 participants, including both healthy volunteers and people with certain solid tumors like pancreatic or lung cancer. Participants will receive a single injection of RAD301 and undergo several PET scans to see where the tracer goes in the body and measure its radiation dose to organs and tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • United Theranostics

    RECRUITING

    Princeton, New Jersey, 08540, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.